Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182636 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 601
- Enrollment target
NCT01182636: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT01182636 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 601 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01182636, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 601 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research \& Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%) topical gel (Galderma Laboratories) in patients with acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Adapalene
- DRUG Differin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01182636
The ClinicalTrials.gov registry entry for NCT01182636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01182636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01182636 about?
NCT01182636 is a clinical study titled "Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris". The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research \& Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%) topical gel (Galderma Laboratories) in patients with acne vulgaris.
What is the current status of trial NCT01182636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 601 participants. The study started on 2007-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT01182636?
The interventions under investigation include: Placebo (DRUG), Adapalene (DRUG), Differin® (DRUG).
Who is sponsoring clinical trial NCT01182636?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.